ArticleNanomedicine (London, England)2025
Specific quantification of intact lipid nanocapsules in rats using FRET: biodistribution and PBPK model development.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Overview on Lipid Nanocapsules: Exploring the Role in Precision Cancer Treatment and Lymphatic Drug Distribution.Advanced pharmaceutical bulletin · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsOne major challenge is to quantify intact nanoparticles specifically to understand the pharmacokinetics (PK) of nanomedicines. Lipid nanocapsules (LNC) carrying Förster resonance energy transfer (FRET) trackers have been previously developed, and a quantification method has been applied in blood samples. MATERIALS &
methodA quantification method in liver, spleen, and lungs was developed, and the biodistribution of intact FRET-LNC of 50 nm (FRET-LNC-50) in rats after intravenous injection was performed.
resultsFRET-LNC-50 were extracted from organs using a newly developed extraction method, allowing their integrity preservation and quantification. This method allowed the assessment of the biodistribution study of intact LNC. A non-compartmental PK analysis was performed to calculate PK parameters. The most exposed organ was the liver, with a longer half-life than blood and other organs. The availability of specific biodistribution data allowed the development of the first physiologically based PK (PBPK) model, which represents an ideal platform to further aggregate biodistribution data from various nanoparticle types and to bring insight into PK mechanisms and structure-properties relationships of nanoparticles.
conclusionThis study presents the first biodistribution analysis of intact LNC using a validated quantification method, enabling the development of a PBPK model that improves the understanding of nanoparticle PK mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.